Herring RA, Shojaee-Moradie F, Garesse R, Stevenage M, et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute
Insulin Withdrawal and Development of Ketoacidosis in People With Type 1
Diabetes. Diabetes Care 2020 Jul 8. pii: dc19-2579. doi: 10.2337/dc19-2579.
PMID: 32641376